Try
Wave Life Sciences Ltd.
WVEUnited States
51 filed reports · 326 financial concepts · 0 earnings calls · 0 media appearances
Filed reports
51 reports · Sep 2015 to Jun 2026Each report counts once it has at least one extracted financial fact.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 33 | 2,906 | Sep 2015 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 11 | 3,198 | Dec 2015 to Dec 2025 |
| Annual · 10-K/ASEC EDGAR | 7 | 7 | Dec 2019 to Dec 2025 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 10-Q | Jun 30, 2026 | Jul 30, 2026 | 250 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | Apr 28, 2026 | 127 | Open |
| FY2025 | 10-K/A | Dec 31, 2025 | Apr 30, 2026 | 1 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Feb 26, 2026 | 563 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Nov 10, 2025 | 152 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Jul 30, 2025 | 86 | Open |
| FY2025 Q1 | 10-Q | Mar 31, 2025 | May 8, 2025 | 85 | Open |
| FY2024 | 10-K/A | Dec 31, 2024 | Apr 29, 2025 | 1 | Open |
| FY2024 | 10-K | Dec 31, 2024 | Mar 4, 2025 | 280 | Open |
| FY2024 Q3 | 10-Q | Sep 30, 2024 | Nov 12, 2024 | 103 | Open |
| FY2024 Q2 | 10-Q | Jun 30, 2024 | Aug 8, 2024 | 76 | Open |
| FY2024 Q1 | 10-Q | Mar 31, 2024 | May 10, 2024 | 79 | Open |
Financial data
326 concepts · 6,111 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial300 concepts · 5,662 facts · Dec 2013 to Jul 2026
- Net income loss63 · Dec 2013 to Jun 2026
- Operating expenses (US GAAP)63 · Dec 2013 to Jun 2026
- Cash and cash equivalents at carrying value62 · Dec 2013 to Jun 2026
- Comprehensive income net of tax61 · Dec 2013 to Jun 2026
- General and administrative expense (US GAAP)61 · Dec 2013 to Jun 2026
- Income tax expense benefit61 · Dec 2013 to Jun 2026
- Nonoperating income expense61 · Dec 2013 to Jun 2026
- Operating income loss61 · Dec 2013 to Jun 2026
- Other comprehensive income loss foreign currency transaction and translation adjustment net of tax61 · Dec 2013 to Jun 2026
- Other nonoperating income expense61 · Dec 2013 to Jun 2026
- Research and development expense61 · Dec 2013 to Jun 2026
- Increase decrease in accounts payable60 · Dec 2013 to Jun 2026
- Payments to acquire property plant and equipment60 · Dec 2013 to Jun 2026
- Property plant and equipment net59 · Dec 2013 to Jun 2026
- Restricted cash and cash equivalents noncurrent59 · Dec 2013 to Jun 2026
- Stockholders equity (US GAAP)59 · Dec 2013 to Jun 2026
- Accounts payable current57 · Dec 2014 to Jun 2026
- Accrued liabilities and other liabilities57 · Dec 2014 to Jun 2026
- Accumulated other comprehensive income loss net of tax57 · Dec 2014 to Jun 2026
- Allocated share based compensation expense57 · Mar 2015 to Jun 2026
- Assets57 · Dec 2014 to Jun 2026
- Assets current57 · Dec 2014 to Jun 2026
- Common stock shares issued57 · Dec 2014 to Jun 2026
- Common stock shares outstanding57 · Dec 2014 to Jun 2026
Geography25 concepts · 375 facts · Dec 2013 to Dec 2025
- Income tax expense benefit109 · Dec 2013 to Dec 2020
- Open tax year41 · Dec 2015 to Dec 2025
- Property, Plant & Equipment, Net29 · Dec 2014 to Dec 2017
- Income loss from continuing operations before income taxes extraordinary items noncontrolling interest28 · Dec 2013 to Dec 2025
- Current income tax expense benefit18 · Dec 2015 to Dec 2025
- Effective income tax rate reconciliation change in deferred tax assets valuation allowance16 · Dec 2013 to Dec 2025
- Effective income tax rate reconciliation foreign income tax rate differential16 · Dec 2013 to Dec 2025
- Deferred income tax expense benefit15 · Dec 2013 to Dec 2025
- Effective income tax rate reconciliation at federal statutory income tax rate15 · Dec 2013 to Dec 2025
- Singapore14 · Dec 2013 to Dec 2024
- Effective income tax rate continuing operations12 · Dec 2013 to Dec 2024
- Effective income tax rate reconciliation other adjustments12 · Dec 2015 to Dec 2024
- Effective income tax rate reconciliation tax credits12 · Dec 2015 to Dec 2024
- Effective income tax rate reconciliation change in enacted tax rate10 · Dec 2015 to Dec 2024
- Japan9 · Dec 2016 to Dec 2025
- Effective income tax rate reconciliation other reconciling items percent4 · Dec 2023 to Dec 2025
- Effective income tax rate reconciliation tax credits research2 · Dec 2025
- Income tax reconciliation change in deferred tax assets valuation allowance2 · Dec 2025
- Income tax reconciliation foreign income tax rate differential2 · Dec 2025
- Income tax reconciliation other reconciling items2 · Dec 2025
- Income tax reconciliation tax credits research2 · Dec 2025
- United States2 · Dec 2025
- Effective income tax rate reconciliation nondeductible expense share based compensation cost1 · Dec 2025
- Income tax reconciliation income tax expense benefit at federal statutory income tax rate1 · Dec 2025
Product1 concepts · 74 facts · Dec 2022 to Jun 2026
- Research and development expense74 · Dec 2022 to Jun 2026
Segments
449 factsFigures broken down by business line, region, product or another axis the company reports on.
Statement geographicalsrt:StatementGeographicalAxis6 members · 215 facts
- SG111 · Dec 2016 to Dec 2025
- GB26 · Jun 2017 to Dec 2025
- US25 · Jun 2018 to Dec 2025
- Rest Of World23 · Dec 2016 to Dec 2025
- JP19 · Dec 2016 to Dec 2025
- IE11 · Dec 2016 to Dec 2020
Statement geographicalus-gaap:StatementGeographicalAxis9 members · 160 facts
- SG60 · Dec 2013 to Mar 2018
- JP25 · Dec 2013 to Mar 2018
- US16 · Dec 2013 to Mar 2018
- Us14 · Dec 2014 to Dec 2017
- Rest Of World13 · Dec 2013 to Dec 2017
- Asia13 · Dec 2014 to Sep 2017
- IE9 · Mar 2016 to Mar 2018
- GB8 · Jun 2016 to Mar 2018
- Jp2 · Dec 2016 to Dec 2017
Product or service10 members · 74 facts
- AATD Program14 · Dec 2022 to Jun 2026
- INHBE Program13 · Dec 2023 to Jun 2026
- DMD Programs8 · Dec 2022 to Jun 2026
- HD Programs8 · Dec 2022 to Jun 2026
- Other Research And Development Expenses Including PNPLA3 Additional Preclinical Programs PRISM7 · Dec 2023 to Jun 2026
- DMD Program6 · Mar 2024 to Sep 2025
- HD Program6 · Mar 2024 to Sep 2025
- Other Research And Development Expenses Including RNA Editing PRISM Others6 · Mar 2024 to Sep 2025
- ALS And FTD Programs Discontinued3 · Dec 2022 to Dec 2024
- Other Research And Development Expenses Including Inhbe Rna Editing Prism Others3 · Dec 2022 to Dec 2024
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
Transcripts with management claims and analyst questions, one per fiscal period.
No earnings-call transcripts for this company.
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.